Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01351519 : A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Clinically documented primary brain tumor for which surgical resection is indicated.

- Age 18 years and older.

- ECOG Performance status less than or equal to 2.

- Laboratory values as follows:

Leukocytes greater than or equal to 3,000. ANC greater than or equal to 1,500. Platelets
greater than or equal to 100,000. Total Bilirubin WNL. AST/ALT less than or equal to 2.5
times ULN. Creatinine WNL. or Creatinine Clearance greater than or equal to
60ml/min/1.73m2 if SCr above institutional normal.

-Ability to provide informed consent or consent from a Legally Authorized Representative.

Exclusion Criteria:

- Receipt of an investigational agent within 30 days.

- Allergy to ALA or similar compounds.

- Personal or family history of porphyria.

- Uncontrolled intercurrent illness.

- Inability to comply with the protocol.

- Pregnancy, breastfeeding.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557